Granted Patent B2

US 12,533,318 · App. 17/638,916 · Granted Jan 27, 2026

Inventors: Maria Monica Castellanos Mantilla (Rockville, MD); Andrzej Stanislaw Pitek (Rockville, MD)

Assignee: GlaxoSmithKline Biologicals SA

A61K9/1277A61K47/6911B01L3/502715B01L3/50273B01L2300/0681B01L2300/0861B01L2400/0487

Abstract

Claims (24)

1 . A method of making a lipid nanoparticle (LNP) in a microfluidic device;

the LNP comprising a liposome and a ribonucleic acid (RNA); the liposome encapsulating at least one molecule of the RNA, thereby forming the LNP; the liposome comprising lipids; the lipids comprising an ionizable cationic lipid;

the microfluidic device comprising a mixing chamber, at least two of a first inlet channel into the mixing chamber, and at least one of a second inlet channel into the mixing chamber; the microfluidic device comprising twice as many of the first inlet channels into the mixing chamber as the second inlet channel into the mixing chamber; the second inlet channel into the mixing chamber being located between the at least two of the first inlet channels into the mixing chamber; each first inlet channel into the mixing chamber having a first cross-sectional area; the at least two of the first inlet channel into the mixing chamber having a total of the first cross-sectional areas, which is m; each second inlet channel into the mixing chamber having a second cross-sectional area; the at least one of the second inlet having a total of the second cross-sectional area, which is n; m/n being a positive number of greater than 1;

the method comprising:

(a) mixing in the mixing chamber a first solution and a second solution, thereby obtaining a mixed material;

the first solution: (i) being delivered into the mixing chamber through the at least two of the first inlet channels into the mixing chamber, (ii) comprising an organic solvent and the lipids, and (iii) having a flow rate of volume per unit time into the microfluidic device, which is x; and

the second solution: (i) being delivered into the mixing chamber through the at least one of the second inlet channel into the mixing chamber, (ii) being an aqueous solution, (iii) comprising the RNA, and (iv) having a flow rate of volume per unit time into the microfluidic device, which is y; y and x being positive numbers and having a ratio of y:x of from 1.5:1 to 3:1 and having a total flow rate of the first solution and second solution combined into the mixing chamber of at least 25 mL per min per mm 2 of cross-sectional area of the mixing chamber perpendicular to the flow through the mixing chamber; the mixed material comprising the LNP and the solvent; and

(b) removing the solvent from the mixed material.

2 . The method of claim 1 , wherein the ratio y:x is about 2:1.

3 . The method of claim 2 , wherein the total flow rate of the first solution and second solution combined into the mixing chamber is from 27 mL per min per mm 2 of cross-sectional area of the mixing chamber perpendicular to the flow through the mixing chamber to 63 mL per min per mm 2 of cross-sectional area of the mixing chamber perpendicular to the flow through the mixing chamber.

4 . The method of claim 1 , wherein the total flow rate of the first solution and second solution combined is no more than 69 mL per min per mm 2 of cross-sectional area of the mixing chamber perpendicular to the flow through the mixing chamber.

5 . The method of claim 1 , wherein the linear fluid velocity within the at least two of the first inlet channel into the mixing chamber is from 6250 cm/min to 46875 cm/min.

6 . The method of claim 1 , wherein the total flow rate of the first solution and second solution combined into the mixing chamber is 25 mL/min/mm 2 .

7 . The method of claim 1 , wherein the organic solvent comprises from 70% (v/v) to 100% (v/v) ethanol.

8 . The method of claim 1 , wherein the first solution comprises at least 1 mg/ml of the lipids.

9 . The method of claim 1 , wherein the microfluidic device comprises a plurality of the mixing chambers.

10 . The method of claim 9 further comprising a first pump and a second pump; the first pump supplying the first solution to each mixing chamber in the plurality of the mixing chambers; and the second pump supplying the second solution to each mixing chamber in the plurality of the mixing chambers, wherein the mixed material from all the mixing chambers is collected before (b).

11 . The method of claim 1 , wherein at least 90% by mass of the RNA is encapsulated in the liposomes.

12 . The method of claim 1 , wherein the average liposome size is 140 nm or lower.

13 . The method of claim 1 , wherein the liposome polydispersity is 0.5 or lower.

14 . The method of claim 1 , wherein the lipids further comprise a zwitterionic lipid, a sterol, and a conjugated lipid.

15 . The method of claim 14 , wherein: the zwitterionic lipid comprises 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC); the conjugated lipid comprises a poly(ethylene glycol)-conjugated (PEGylated) lipid; the PEGylated lipid comprises 1, 2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)] or 1,2-dimyristoyl-sn-glycerol, methoxypoly(ethylene glycol).

16 . The method of claim 1 , the method further comprising after (a) sterilizing by filtering.

17 . The method of claim 1 , wherein the liposome encapsulating the at least one RNA has an EC50 of less than 0.1 ng/well.

Assignments (1)

Continuity (2)

References Cited (135)